Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NASDAQ:BCRX

BioCryst Pharmaceuticals Q3 2026 Earnings Date & Estimates

BioCryst Pharmaceuticals logo
$7.65 -0.13 (-1.67%)
Closing price 10/23/2026 04:00 PM Eastern
Extended Trading
$7.67 +0.02 (+0.26%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioCryst Pharmaceuticals is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from BioCryst Pharmaceuticals in Q3 2026

BioCryst Pharmaceuticals is expected to post earnings of $0.0919 per share on revenue of $165.67 million. In the same quarter a year earlier BioCryst Pharmaceuticals reported $0.06 per share on revenue of $159.40 million. BioCryst Pharmaceuticals last reported on August 5, 2026, posting $0.30 per share and beating the $0.1542 consensus estimate. BioCryst Pharmaceuticals has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$0.0919
Expected Revenue
$165.67 million
Prior-Year EPS
$0.06
Prior-Year Revenue
$159.40 million
Expected EPS Growth
+53.1%
Expected Revenue Growth
+3.9%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$0.30 (Beat by +$0.1458)
Last Quarter Revenue
$218.25 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

BioCryst Pharmaceuticals Q3 2026 Earnings FAQ

BioCryst Pharmaceuticals (NASDAQ:BCRX) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

BioCryst Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Wednesday, November 4, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect BioCryst Pharmaceuticals to post earnings of $0.0919 per share for Q3 2026.

The consensus revenue estimate for BioCryst Pharmaceuticals is $165.67 million for Q3 2026.

BioCryst Pharmaceuticals Earnings Headlines

BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Wall Street Zen
October 24 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151396
BioCryst to Report Third Quarter 2026 Financial Results on November 4
October 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385876/29446/en/biocryst-to-report-third-quarter-2026-financial-results-on-november-4.html
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.tc pixel
 |  Banyan Hill Publishing (Ad)
BioCryst Wins FDA Approval For Orladeyo Oral Pellets In HAE Patients Aged 12 And Older
October 21, 2026  |  rttnews.comhttps://www.rttnews.com/3701143/biocryst-wins-fda-approval-for-orladeyo-oral-pellets-in-hae-patients-aged-12-and-older.aspx
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
October 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/21/3385361/29446/en/biocryst-announces-u-s-fda-approval-of-orladeyo-150-mg-oral-pellets-for-adults-and-adolescents-with-hae.html
Head-To-Head Review: Syndax Pharmaceuticals (NASDAQ:SNDX) & BioCryst Pharmaceuticals (NASDAQ:BCRX)
October 21, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31142509
See More BioCryst Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioCryst Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCryst Pharmaceuticals and other key companies, straight to your email.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals (NASDAQ:BCRX) is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst’s primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets. Its development efforts have also included antiviral and other specialty-care programs, reflecting the company’s broader focus on small-molecule medicines for medically underserved patient populations.

View BioCryst Pharmaceuticals Profile
Earnings Tools